Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

13,409 total articles

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

Beam Therapeutics presented encouraging topline clinical data from its Phase 1/2 trial of BEAM-302, an investigational one-time gene editing therapy targeting the root cause of Alpha-1 Antitrypsin Deficiency (AATD). The data suggest durable correction of the PiZ mutation that causes both liver and lung disease manifestations, supporting plans for a…

Toll Brothers Announces Cameron Cove Now Open in Marietta, Georgia

Toll Brothers Announces Cameron Cove Now Open in Marietta, Georgia

Toll Brothers, Inc., a leading luxury home builder, has announced the opening of its new community, Cameron Cove, in Marietta, Georgia. Featuring flexible single-family home designs and resort-style amenities, Cameron Cove offers homes priced from the mid-$600,000s in a sought-after school district and convenient location. This expansion reinforces…

Toll Brothers Announces Model Home Grand Opening at Toll Brothers at South Main Community in Milpitas, California

Toll Brothers Announces Model Home Grand Opening at Toll Brothers at South Main Community in Milpitas, California

Toll Brothers, Inc. announced the grand opening of model homes at its new all-electric luxury townhome community, Toll Brothers at South Main, located in Milpitas, California. The community offers 3-bedroom, 3-bathroom homes with modern features and is priced from $1.2 million. The development emphasizes luxury living with convenient access to majo…

Algorhythm Holdings Announces Expanded Contract with Procter & Gamble India for SemiCab’s Freight Services

Algorhythm Holdings Announces Expanded Contract with Procter & Gamble India for SemiCab’s Freight Services

Algorhythm Holdings announced that its subsidiary, SemiCab India, secured a significant expansion of its managed freight services contract with Procter & Gamble India. The annual contract value increased by 32% to $4.2 million, with lane volumes growing from 42 to 65 lanes covering key manufacturing and distribution corridors across India. This mar…

Letter to Shareholders from CEO Dr. Ryan Saadi

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Holdings Inc. reports a 51% reduction in operational losses from 2024 to 2025 and continued progress into 2026 while advancing its AI-driven and cell therapy initiatives. The company focuses on disciplined capital allocation, potential acquisitions to generate revenue, and aligning incentives with performance milestones to build a susta…

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio announced positive Phase 2 VIBRANT trial data for verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug demonstrated statistically significant and clinically meaningful improvements in asthma symptom control, reductions in nasal polyp scores, and decreased reliance on corticosteroids…

Arvinas Employees Give Back During Company-wide Impact Day

Arvinas Employees Give Back During Company-wide Impact Day

Arvinas, Inc., a clinical-stage biotech company specializing in targeted protein degradation therapies, held its fourth annual Impact Day with employees nationwide volunteering in community service projects. Activities included supporting families at Ronald McDonald House, creating blankets for hospitalized children, serving meals to cancer patient…

POET Technologies Announces Closing of US$400 Million Investment

POET Technologies Announces Closing of US$400 Million Investment

POET Technologies announced the closing of a $400 million investment through a registered direct offering, issuing over 19 million shares and warrants at a premium price. The funds will be used to significantly expand manufacturing capacity, support corporate development including acquisitions, accelerate R&D, and grow operations in Asia. This stra…

CBAK Energy Reports First Quarter 2026 Unaudited Financial Results

CBAK Energy Reports First Quarter 2026 Unaudited Financial Results

CBAK Energy Technology reported strong first quarter 2026 results with consolidated net revenues nearly doubling year-over-year to $69.62 million, driven by expanded production capacity and significant growth in light electric vehicles and battery raw materials segments. While revenues surged, gross margins declined due to ramp-up costs and delayed…

Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures

Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures

Royal Philips introduces SmartIQ, a new imaging technology integrated into its Azurion image-guided therapy system designed for coronary procedures. SmartIQ offers improved image quality with over 50% less X-ray radiation dose compared to previous protocols, addressing the critical trade-off in coronary imaging between clarity and radiation exposur…

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Nexentis Technologies, a Nasdaq-listed company, announced that its subsidiary MitoCareX Bio has generated an optimized hit molecule with improved pharmaceutical properties in its drug discovery program. Utilizing the proprietary MITOLINE® platform, MitoCareX has overcome major challenges in targeting mitochondrial SLC25 carrier proteins, advancing …